508 posters,  9 sessions,  4 topics,  1544 authors,  556 institutions

ePostersLive® by SciGen® Technologies S.A. All rights reserved.

IS-4
Overcoming HER2/estrogen receptor (ER) cross-talk: neratinib ± fulvestrant in ER+ HER2-mutant metastatic breast cancer (MBC) in the phase II SUMMIT trial
Thursday, May 4th, 11:45 AM - Monitor IS-1

Enter Poster ID (e.gGoNextPreviousCurrent